遺伝性癌症候群、癌家族症候群
- 関
- hereditary neoplastic syndrome
WordNet
- type genus of the family Cancridae (同)genus Cancer
- the fourth sign of the zodiac; the sun is in this sign from about June 21 to July 22 (同)Cancer the Crab, Crab
- (astrology) a person who is born while the sun is in Cancer (同)Crab
- a small zodiacal constellation in the northern hemisphere; between Leo and Gemini
- a pattern of symptoms indicative of some disease
- a complex of concurrent things; "every word has a syndrome of meanings"
- any malignant growth or tumor caused by abnormal and uncontrolled cell division; it may spread to other parts of the body through the lymphatic system or the blood stream (同)malignant neoplastic disease
PrepTutorEJDIC
- (疾患の徴候となる一群の)症徴候,症候群 / (事件・社会的状態などのパターンを示す)徴候形態
- 〈U〉〈C〉『がん』 / 〈U〉〈C〉害悪 / 《Cancer》(星座の)カニ座
- 世襲の,親譲りの / 遺伝的な,遺伝性の
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- [Risk-adapted surveillance : Focus on familial breast and ovarian cancer].
- Rhiem K1, Schmutzler RK.Author information 1Direktorin des Zentrums für Familiären Brust- und Eierstockkrebs, Universitätsklinikum Köln, Kerpener Str. 34, 50931, Köln, Deutschland.AbstractBreast cancer surveillance programs for the general population are not adequate for the small number of women with hereditary breast and ovarian cancer syndrome. Breast cancer screening for women in Germany starts at the age of 50 years, but nearly half of all women with familial risk are already diagnosed with breast cancer at that time. Moreover, mammography alone is not suitable for an early diagnosis of breast cancer in young women from high-risk families. Their typical dense breast tissue causes a high rate of false-negative cases. Therefore, national and international prospective clinical trials were initiated to offer a multimodal breast cancer surveillance program including magnetic resonance tomography for the breast and semi-annual screening intervals to women with BRCA1/2 mutations and those from high-risk families who tested negative for BRCA1/2 mutations. This program will currently be evaluated by the 15 centers of the German Consortium for Hereditary Breast and Ovarian Cancer.
- Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz.Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz.2014 Mar;57(3):307-11. doi: 10.1007/s00103-013-1910-3.
- Breast cancer surveillance programs for the general population are not adequate for the small number of women with hereditary breast and ovarian cancer syndrome. Breast cancer screening for women in Germany starts at the age of 50 years, but nearly half of all women with familial risk are already d
- PMID 24562705
- DNA testing and molecular screening for colon cancer.
- Carethers JM.Author information Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan. Electronic address: jcarethe@umich.edu.AbstractColon cancer develops and progresses as a consequence of abnormal cellular molecular changes, many of which result in mutant DNA. Modern molecular techniques allow examination of individual patient genetic data that ascribe risk, predict outcome, and/or modify an approach to therapy. DNA testing and molecular screening are in use today and are becoming a critical and necessary part of routine patient care. Assessing at-risk patients for hereditary colon cancer is predicted to move from individual gene testing that is commonly performed today to whole exome or whole genome sequencing, providing additional vast information of the patient's genome that might not be related to the colon cancer syndrome. Detecting mutant DNA from shed tumor cells in fecal material for colon cancer screening will increase in diagnostic accuracy over time, with improvements in the panel of mutant DNA being examined and through clinical testing. DNA mutations and other molecular changes detected directly from within the colon cancer help to inform and guide the physician for the best approach for optimal patient care and outcome. The use of epidermal growth factor receptor-targeted therapy in advanced colon cancer patients requires knowledge of the mutation status for KRAS and BRAF genes, and knowing the mutational status of PIK3CA may predict how patients respond to aspirin to prevent colon cancer recurrence. Biologically driven decision-making, or precision medicine, is becoming increasingly adopted for optimal care and outcome for colon cancer patients. Gastroenterologists will need to be increasingly aware.
- Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.Clin Gastroenterol Hepatol.2014 Mar;12(3):377-81. doi: 10.1016/j.cgh.2013.12.007. Epub 2013 Dec 17.
- Colon cancer develops and progresses as a consequence of abnormal cellular molecular changes, many of which result in mutant DNA. Modern molecular techniques allow examination of individual patient genetic data that ascribe risk, predict outcome, and/or modify an approach to therapy. DNA testing and
- PMID 24355100
- Communication and technology in genetic counseling for familial cancer.
- Lynch HT1, Snyder C, Stacey M, Olson B, Peterson SK, Buxbaum S, Shaw T, Lynch PM.Author information 1Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE, USA.AbstractWhen a cancer predisposing germline mutation is detected in an index case, the presence of the underlying syndrome is confirmed and the potential for predictive testing of at-risk relatives is established. However, the reporting of a positive family history does not routinely lead to communication of information about risk to close, much less distant relatives. This review summarizes information technology utilized to address penetration or 'reach' of knowledge of risk within extended families, including the use of telephone and video counseling to reach distant patients, and anticipate novel internet-based processes for communication between investigators and relatives.
- Clinical genetics.Clin Genet.2014 Mar;85(3):213-22. doi: 10.1111/cge.12317. Epub 2013 Dec 20.
- When a cancer predisposing germline mutation is detected in an index case, the presence of the underlying syndrome is confirmed and the potential for predictive testing of at-risk relatives is established. However, the reporting of a positive family history does not routinely lead to communication o
- PMID 24355094
Japanese Journal
- 遺伝性腎がんのup-to-date (特集 腎泌尿器の遺伝性疾患・難病医療)
- 蓮見 壽史,矢尾 正祐
- 腎臓内科・泌尿器科 = Nephrology & urology 9(5), 483-490, 2019-05
- NAID 40021916028
- 当院における遺伝性乳癌診療の取り組みと現況〜HBOCの診療体制と今後の展望について〜
- 河合 由紀,北村 美奈,木村 由梨,勝元 さえこ,佐藤 智佳,茶野 徳宏,冨田 香,森 毅,梅田 朋子,清水 智治,谷 眞至
- 滋賀医科大学雑誌 32(1), 6-10, 2019-03-15
- … いて乳癌は女性の癌罹患第1位であり,そのうち約5〜10%が遺伝性乳癌といわれている.遺伝性乳癌の約半数以上を占めるBRCA1,BRCA2遺伝子を原因遺伝子とする場合,遺伝性乳癌卵巣癌症候群(Hereditary Breast and Ovarian Cancer syndrome : HBOC)という.遺伝性乳癌を疑う場合に行う遺伝学的検査として,当院では2015年にBRCA1/2遺伝子検査と遺伝カウンセリング体制を自費診療として導入した. …
- NAID 120006633020
- 遺伝性乳癌 : 遺伝性疾患としての意義とコンパニオン診断としての意義を考える
Related Links
- Hisada M, Garber JE, Fung CY, Fraumeni JF Jr, Li FP. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst. 1998;90:606-611. MedlinePlus. National Library of Medicine (US). Multiple ...
- A hereditary cancer syndrome is present when a person, because of an inherited mutation, has an increased risk of developing certain tumors which can already develop at a relatively early age. In most known hereditary ...
- What is the role of genetic counseling in genetic testing for a hereditary cancer syndrome? How is genetic testing done? What do the results of genetic testing mean? Who has access to a person’s genetic test results? Can at ...
★リンクテーブル★
[★]
- 英
- hereditary cancer syndrome
- 関
- 遺伝性癌症候群、遺伝性腫瘍症候群
[★]
- 関
- hereditary cancer syndrome
[★]
- 英
- hereditary cancer syndrome
- 関
- 癌家族症候群
[★]
- 関
- heredity、heritable、inherit、inheritable、inheritable character、inheritance、inherited
[★]
- 同
- 癌腫
- 関
- tumor
[★]